What does GK stand for?

Glucokinase

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Gabriel Knight (computer game) Gallien-Krueger, Inc. Garage Kids (cartoon) Garry Kasparov (chess player) Gatekeeper Gawad Kalinga (Filipino: Give Care) General Knowledge Genesis Knights (gaming clan) Gerichtskasten (German: Pigeon-Hole; law firms) Global Kids, Inc (New York, New York)		Goal Kick Goalkeeper Godo Kaisha (Japan) Golden Key International Honour Society Good Kill (video gaming) Grand Knight (head of VKV fraternity, Philippines) Gravekeeper (YuGiOh cards) Gravity Kills (band) Great Khali (wrestler) Greek

Samples in periodicals archive:

NASDAQ: ARRY) announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

United States : Array BioPharma To Present Clinical Results On ...

Biotin induces the enzyme glucokinase, which plays a role in the catabolism of glucose.

Chromium and biotin for type 2 diabetes

Two product candidates, both glucokinase activators, are scheduled to enter Phase I clinical trials in 2005.

OSI INITIATES PHASE I CLINICAL TRIAL OF PSN357

NASDAQ: ARRY) today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

Array BioPharma to Present Clinical Results on Diabetes Drug at ...

Nasdaq: ARRY) today announced positive top-line data from a Phase 1 clinical trial in patients with Type 2 diabetes with its novel small molecule glucokinase activator (GKA), ARRY-403.

Array BioPharma Reports Positive Results of Its Oral Glucokinase ...

During the quarter, we also initiated dosing on an exciting glucokinase activator, ARRY-403, for Type II diabetes patients.

Array BioPharma Reports Financial Results for the Third Quarter of ...

Nasdaq: ARRY) today announced that it has dosed its first Type 2 diabetic patient in a Phase 1 clinical trial with its novel small molecule glucokinase activator (GKA), ARRY-403.

Array BioPharma Initiates Clinical Trial in Type 2 Diabetic Patients

Initiating clinical development of a novel glucokinase activator for Type II diabetes During the first quarter of calendar 2009, Array plans to initiate Phase 1 clinical development with ARRY-403, a novel glucokinase activator.

Array BioPharma Reports Financial Results for the Second Quarter of ...